Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Christ

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Journal of Medicinal Chemistry|May 2, 2003
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitorsRobert J Cherney, James J-W Duan, Matthew E Voss, et al.
Journal of Medicinal Chemistry|April 14, 2017
Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L BromodomainsLéa Bouché, Clara D Christ, Stephan Siegel, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 11, 2019
Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in miceSara L Jepsen, Kaare V Grunddal, Nicolai J Wewer Albrechtsen, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 22, 2021
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput ScreeningStefan Gradl, Holger Steuber, Joerg Weiske, et al.
Blood|October 4, 2017
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisibV Koneti Rao, Sharon Webster, Virgil A S H Dalm, et al.
Journal of Medicinal Chemistry|April 15, 2016
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2Erik Eggert, Roman C Hillig, Silke Koehr, et al.
Journal of Pharmaceutical Sciences|October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerationsKan He, Mingxin Qian, Harvey Wong, et al.
Journal of Medicinal Chemistry|September 16, 2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)Bertrand Le Bourdonnec, Rolf T Windh, Christopher W Ajello, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2007
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicityJames R Pruitt, Douglas G Batt, Dean A Wacker, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Journal of Medicinal Chemistry|May 2, 2003
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitorsRobert J Cherney, James J-W Duan, Matthew E Voss, et al.
Journal of Medicinal Chemistry|April 14, 2017
Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L BromodomainsLéa Bouché, Clara D Christ, Stephan Siegel, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 11, 2019
Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in miceSara L Jepsen, Kaare V Grunddal, Nicolai J Wewer Albrechtsen, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 22, 2021
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput ScreeningStefan Gradl, Holger Steuber, Joerg Weiske, et al.
Blood|October 4, 2017
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisibV Koneti Rao, Sharon Webster, Virgil A S H Dalm, et al.
Journal of Medicinal Chemistry|April 15, 2016
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2Erik Eggert, Roman C Hillig, Silke Koehr, et al.
Journal of Pharmaceutical Sciences|October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerationsKan He, Mingxin Qian, Harvey Wong, et al.
Journal of Medicinal Chemistry|September 16, 2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)Bertrand Le Bourdonnec, Rolf T Windh, Christopher W Ajello, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2007
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicityJames R Pruitt, Douglas G Batt, Dean A Wacker, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Pageof 12